Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Major, 1993, Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group Study, Cancer, 71, 1702, 10.1002/cncr.2820710440 Levenback, 1992, Resection of pulmonary metastases from uterine sarcomas, Gynecol. Oncol., 45, 202, 10.1016/0090-8258(92)90286-R Sutton, 1996, Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study, Gynecol. Oncol., 62, 226, 10.1006/gyno.1996.0220 Hensley, 2002, Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial, J. Clin. Oncol., 20, 2824, 10.1200/JCO.2002.11.050 Hensley, 2008, Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial, Gynecol. Oncol., 109, 329, 10.1016/j.ygyno.2008.03.010 Hensley, 2008, Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study, Gynecol. Oncol., 109, 323, 10.1016/j.ygyno.2008.02.024 Sutton, 1992, Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Am. J. Obstet. Gynecol., 166, 556, 10.1016/0002-9378(92)91671-V Look, 2004, Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study, Gynecol. Oncol., 92, 644, 10.1016/j.ygyno.2003.11.023 Garcia-Carbonero, 2004, Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study, J. Clin. Oncol., 23, 5484, 10.1200/JCO.2005.05.028 Delaloge, 2001, Ecteinasidin-743: a marine-derived compound in advanced, pre-treated sarcoma patients—preliminary evidence of activity, J. Clin. Oncol., 19, 1248, 10.1200/JCO.2001.19.5.1248 Thigpen, 1991, Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study, J. Clin. Oncol., 9, 1962, 10.1200/JCO.1991.9.11.1962 Muss, 1990, Mitoxantrone in the treatment of advanced uterine sarcoma: a phase II trial of the Gynecologic Oncology Group, Am. J. Clin. Oncol., 13, 32, 10.1097/00000421-199002000-00009 Asbury, 1998, Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study, Am. J. Clin. Oncol., 21, 145, 10.1097/00000421-199804000-00010 Rose, 1998, Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Gynecol. Oncol., 70, 267, 10.1006/gyno.1998.5080 Slayton, 1991, A Phase II clinical trial of diazoquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Invest. New Drugs, 9, 207, 10.1007/BF00175091 Slayton, 1987, Phase II trial of etoposide in the management of advanced or recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Cancer Treat. Rep., 71, 1303 Miller, 2000, Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study, Am. J. Clin. Oncol., 23, 355, 10.1097/00000421-200008000-00009 Gallup, 2003, Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Gynecol. Oncol., 89, 48, 10.1016/S0090-8258(02)00136-1 Sutton, 1999, Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, Gynecol. Oncol., 74, 346, 10.1006/gyno.1999.5463 McMeekin, 2007, A Phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group Study, Gynecol. Oncol., 105, 508, 10.1016/j.ygyno.2007.01.019 Smith, 2002, Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group, Gynecol. Oncol., 84, 140, 10.1006/gyno.2001.6482 Olson, 1994, Vascular permeability factor gene expression in normal and neoplastic human ovaries, Cancer. Res., 54, 276 Guidi, 1995, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia, J. Natl. Cancer Inst., 87, 1237, 10.1093/jnci/87.16.1237 Guidi, 1996, Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma, Cancer, 78, 454, 10.1002/(SICI)1097-0142(19960801)78:3<454::AID-CNCR12>3.0.CO;2-Y Chen, 1999, Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival, Gynecol. Oncol., 74, 235, 10.1006/gyno.1999.5418 Holash, 2002, VEGF-Trap: A VEGF blocker with potent antitumor effects, Proc. Natl. Acad. Sci. U. S. A., 99, 11393, 10.1073/pnas.172398299 Dupont, 2005, Safety and pharmacokinetics of intravenous VEGF-Trap in a phase I clinical trial of patients with advanced solid tumors, Proc. Am. Soc. Clin. Oncol., 23, 3029, 10.1200/jco.2005.23.16_suppl.3029 Investigator's Brochure SU011248 (December 2005). Pfizer, Inc. and Affiliates, New York, New York. Sill MW, Yothers G. A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials, Technical Report 2006-08, Department of Biostatistics, University at Buffalo. Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 24, 16, 10.1200/JCO.2005.02.2574 Demetri, 2006, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 368, 1329, 10.1016/S0140-6736(06)69446-4 Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133–40. Keohan, 2008, Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial, J. Clin. Oncol., 26, 10.1200/jco.2008.26.15_suppl.10533 Vigil, 2008, Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas, J. Clin. Oncol., 26, 10.1200/jco.2008.26.15_suppl.10535 Van Glabbeke, 2002, Progression-free rate as the principal end-point for phase II trials in soft tissue sarcoma, Eur. J. Cancer, 38, 543, 10.1016/S0959-8049(01)00398-7